Key Highlights
- Lyell Immunopharma (NASDAQ:LYEL) trades at USD 15.73 after a 1.91% latest-session gain, with a 1W move of 42.95% and a 1M move of 72.23% in a published screener snapshot taken November 5, 2026.
- The company reported third quarter 2026 results on November 4, 2026: net loss of USD 45.5 million versus USD 38.8 million a year earlier, and cash of USD 194.0 million at September 30, 2026.
- It also announced an USD 80.0 million private Placement and says cash plus proceeds should fund operations into 2028, against a market cap near USD 382.28 million on 24.51 million shares.
- The 3M gain is 12.32%, but the 6M move is negative 21.10% and the YTD move is negative 49.79%, so the rally sits inside a deep drawdown with a 52-week range of USD 7.20 to USD 45.00.
What Moved Lyell Immunopharma (42.95% in 1W, 72.23% in 1M)
Lyell Immunopharma (NASDAQ:LYEL) closed the latest session in the screener snapshot at USD 15.73, up 1.91%. Its 1W gain of 42.95% and 1M gain of 72.23% place it among the best-performing small caps (market cap 300 million to 2 billion USD) on both windows. The week includes the November 4, 2026 release of third quarter results. Net loss widened to USD 45.5 million from USD 38.8 million, with Research and Development at USD 40.9 million versus USD 28.2 million and general and administrative at USD 9.3 million versus USD 10.7 million. Revenue was USD 3 thousand. Cash, cash equivalents and marketable securities stood at USD 194.0 million, down from USD 247.2 million at December 31, 2025.
Why a Clinical Stage Cell Therapy Stock Re-Rates
The company release points to pivotal program data as the main driver, though the price move cannot be tied to one headline. In the PiNACLE trial of ronde-cel in third-line and later large B-cell lymphoma, 44 patients were efficacy-evaluable. The overall response rate was 91% and the complete response rate was 77%, with continued complete response of 92% at 6 months and 75% at 12 months. No grade 3 or higher cytokine release syndrome was seen, and grade 3 or higher ICANS occurred in 9% of patients. Enrollment should finish by year end, pivotal data is expected in mid-2027 and a BLA submission in the second half of 2027. The USD 80.0 million placement extends runway into 2028. General context: data, funding and a low base often re-rate small biotechs.
Valuation, Liquidity and Risks After a Sharp Run
The market cap of about USD 382.28 million is only about 2 times the USD 194.0 million of cash reported at September 30, 2026, simple arithmetic on two published numbers, against a non-GAAP net loss of USD 41.3 million in the quarter. Published coverage shows 8 analysts at a Buy consensus with an average target of USD 37.88, which is not our view. The stock sits USD 29.27 below its 52-week high of USD 45.00 and USD 8.53 above the low. Volume of 83,379 shares in a recent intraday reading shows thin trading: a small number of trades can move the price, spreads can be wide, and the move may reverse.
Where Things Stand
The surge reflects pivotal data, a financing and a deeply sold base rather than one clean catalyst. Lyell Immunopharma (NASDAQ:LYEL) ranks among the small cap leaders on both the 1W gain of 42.95% and the 1M gain of 72.23% in the screener snapshot. After a 3M gain of 12.32%, a 6M loss of 21.10% and a YTD loss of 49.79%, the stock is rebounding inside a larger decline. Investors will watch the ASH presentations from December 12 to 15, 2026, enrollment completion and the mid-2027 pivotal readout.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...